Mode
Text Size
Log in / Sign up
N/A N=262 Randomized Double-blind Treatment

Evaluation of Astigmatic Contact Lenses

Visual Acuity

Enrolled (actual)
262
Serious AEs
0.0%
Results posted
Jul 2018
Primary outcome: Primary: Monocular Distance Visual Acuity (VA) — 258; 263 Eyes

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Investigational Contact Lens (Device); Marketed Contact Lens (Device)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Johnson & Johnson Vision Care, Inc.
Primary completion
May 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Monocular Distance Visual Acuity (VA)
177; 184
PRIMARY
Lens Fit Acceptance
258; 264
PRIMARY
Lens Stability With Blink
258; 264
PRIMARY
Absolute Lens Rotation
255; 261
PRIMARY
Corneal Staining
0; 3
SECONDARY
Overall Comfort
61.4; 52.0
SECONDARY
Overall Handling
63.5; 65.7
SECONDARY
Monocular Distance Visual Acuity (VA)
177; 184

Summary

Randomized, double-masked, 5-visit, bilateral dispensing, parallel group study to demonstrate that the investigational contact lens meets the design requirements related to corneal staining, lens fit, visual acuity and rotational performance as well as subjective comfort and handling. Subjects will wear the contact lenses for a total of 28-36 days.

Eligibility Criteria

Inclusion Criteria

  • 1) Healthy adult males or females age ≥18-40 years of age with signed informed consent.
  • The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
  • Subject must be a habitual soft toric contact lens wearer. Habitual wearer is defined as someone who wears contact lenses for at least 6 hours a day, 5 days a week for the past 30 days.
  • Subject's vertex corrected spherical component of their distance refraction must be between -1.00 to -4.75 Diopter (D) (inclusive) in each eye.
  • Subject's vertex corrected refractive cylinder must be between -0.75 and -1.50 DC (inclusive) in each eye.
  • Subject's refractive cylinder axis must be 180±25 and 90±15 in each eye. 7) The subject must have visual acuity best correctable to 20/25 or better for each eye 8) The subject must read and sign the Informed Consent form.

Exclusion Criteria

  • 1) Women who are pregnant or breastfeeding, 2) Any ocular or systemic allergies or diseases that may contraindicate contact lens wear.
  • Any ocular medications use within the last one month. 4) Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear.
  • Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g., HIV), by self-report.
  • Habitual wearer of extended wear contact lenses. 7) Known sensitivity to Revitalens OcuTec® 8) Any previous history of ocular and/or refractive surgery (e.g., radial keratotomy, PRK, LASIK, etc.).
  • A clinical finding or history of entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion, by self-report.
  • History of binocular vision abnormality or strabismus, by self-report. 11) Habitual wearer of rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months.
  • Employee of investigational clinic (e.g., Investigator, Coordinator, Technician).
  • Participation in any contact lens or lens care product clinical trial within 14 days prior to study enrollment.
  • Clinically significant (grade 3 or higher) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities, bulbar injection or any other abnormalities which would contraindicate contact lens wear.
  • Any history of a contact lens-related corneal inflammatory event within the past year that may contraindicate contact lens wear.
  • Any active ocular infection. 17) Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
  • Any fluctuations in vision due to clinically significant dry eye or other ocular conditions.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03086447). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search